Advertisement

ASCO 2022: Asciminib vs Bosutinib in Pretreated Patients With CML in Chronic Phase
Posted: 07/19/2022 | By: Justine Landin, PhD

At the 2022 ASCO Annual Meeting, Rea et al presented efficacy and safety results from the phase III ASCEMBL study, which compared asciminib to bosutinib in patients diagnosed with chronic myeloid leukemia (CML) in chronic phase who had been pretreated with tyrosine kinase inhibitors.

Question 1 of 5

Which of the following is TRUE regarding patients who received asciminib treatment?

Choose 1

A
24.2% of patients discontinued treatment due to lack of efficacy
B
The median duration of exposure ranged from 1 to 188 weeks
C
Only one new on-treatment death was reported
D
The probability of maintaining major molecular response for 72 weeks or more was 96.7%

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage